Abstract
Epidemiological studies have examined the association between the use of non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of Alzheimer's disease (AD). Recently, a variety of experimental studies indicates that a subset of NSAIDs, such as ibuprofen or flurbiprofen, also have Abeta-lowering properties in both AD transgenic mice and cell cultures of peripheral, glial and neuronal origin. In this trial, we evaluated whether the non-selective NSAID ibuprofen slows disease progression in patients with mild to moderate AD.
Lingua originale | English |
---|---|
pagine (da-a) | 102-110 |
Numero di pagine | 8 |
Rivista | Aging clinical and experimental research |
Volume | 21 |
DOI | |
Stato di pubblicazione | Pubblicato - 2009 |
Keywords
- APOE e4
- Alzheimer Disease